[{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"BOL Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"BOL-DP-o-04","moa":"CB receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kindeva Drug Delivery \/ BOL Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Kindeva Drug Delivery \/ BOL Pharma"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kindeva Drug Delivery \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"12","companyTruncated":"Kindeva Drug Delivery \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation aerosol","sponsorNew":"Kindeva Drug Delivery \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Kindeva Drug Delivery \/ Sandoz"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"Kindeva Drug Delivery \/ Kindeva","highestDevelopmentStatusID":"12","companyTruncated":"Kindeva Drug Delivery \/ Kindeva"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diclofenac Epolamine","moa":"COX1\/COX2","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Kindeva Drug Delivery \/ Kindeva","highestDevelopmentStatusID":"5","companyTruncated":"Kindeva Drug Delivery \/ Kindeva"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Nutriband","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Kindeva Drug Delivery \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"4","companyTruncated":"Kindeva Drug Delivery \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Nutriband","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Kindeva Drug Delivery \/ Nutriband","highestDevelopmentStatusID":"6","companyTruncated":"Kindeva Drug Delivery \/ Nutriband"}]

Find Clinical Drug Pipeline Developments & Deals by Kindeva Drug Delivery

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Kindeva will develop commercial manufacturing processes and clinical supplies for Aversa Fentanyl, integrating Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's fentanyl patch system.

                          Brand Name : Aversa Fentanyl

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 05, 2024

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Nutriband

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : AVERSA™ (fentanyl) combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch system.

                          Brand Name : Aversa

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 04, 2023

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Recipient : Nutriband

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Epoladerm™ (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee.

                          Brand Name : Epoladerm

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 27, 2022

                          Lead Product(s) : Diclofenac Epolamine

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : IND Enabling

                          Recipient : Virpax Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Breyna (Budesonide and Formoterol Fumarate Dihydrate), first approved generic version of AstraZeneca's Symbicort, a drug-device combination product, is indicated for certain patients with asthma or COPD and will be available in 160 /4.5 and 80/4.5 mcg do...

                          Brand Name : Breyna

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 16, 2022

                          Lead Product(s) : Budesonide,Formoterol Fumarate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved

                          Recipient : Viatris

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Albuterol sulfate is used to treat or prevent bronchospasm in patients four years and older with reversible obstructive airway disease, such as asthma, and to prevent exercise-induced bronchospasm.

                          Brand Name : Proventil HFA

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 16, 2021

                          Lead Product(s) : Salbutamol Sulphate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved

                          Sponsor : Sandoz B2B

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The U.S. Food and Drug Administration (FDA) granted tentative approval of budesonide/formoterol fumarate dihydrate products, the first generic version of Symbicort based on an Abbreviated New Drug Application (ANDA).

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 09, 2021

                          Lead Product(s) : Budesonide,Formoterol Fumarate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved

                          Recipient : Viatris

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Under the agreement, Kindeva will develop novel formulations of BOL Pharma’s cannabinoid based drug products delivered by Kindeva’s metered-dose inhaler (MDI) technology.

                          Brand Name : BOL-DP-o-04

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 01, 2020

                          Lead Product(s) : BOL-DP-o-04

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : BOL Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank